# Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

> **NCT04943029** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Carrelizumab
- **DRUG:** Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)
- **DRUG:** Carboplatin
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT04943029
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-20
- **Primary completion:** 2022-05-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943029, "Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04943029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*